P
Philip Stashenko
Researcher at The Forsyth Institute
Publications - 141
Citations - 12300
Philip Stashenko is an academic researcher from The Forsyth Institute. The author has contributed to research in topics: Bone resorption & Osteoclast. The author has an hindex of 56, co-authored 139 publications receiving 11803 citations. Previous affiliations of Philip Stashenko include Boston University & Harvard University.
Papers
More filters
Journal Article
Characterization of a human B lymphocyte-specific antigen.
TL;DR: Removal of the B1 positive population in peripheral blood eliminated all B cells capable or responding to pokeweed mitogen by maturation to Ig-producing cells.
Journal Article
Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption.
TL;DR: IL 1 beta is considerably more potent than TNF and LT in stimulating bone resorption either alone or under synergistic conditions, it is unlikely that TNF or LT are responsible for more than a minor proportion of the total bone-resorbing activity formerly referred to as OAF.
Journal Article
Purification and partial sequence of human osteoclast-activating factor: identity with interleukin 1 beta.
TL;DR: It is concluded that interleukin 1 beta is the major protein with OAF activity produced by lectin-stimulated peripheral blood mononuclear cells and that the m.w., isoelectric point, amino-terminal sequence, and specific activity in the thymocyte proliferation assay are the same for homogeneous OAF and interleucin 1beta.
Journal ArticleDOI
Atp6i -deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification
TL;DR: It is demonstrated that targeted disruption of Atp6i in mice results in severe osteopetrosis and is unique and necessary for osteoclast-mediated extracellular acidification.
Journal Article
Serotherapy of a Patient with a Monoclonal Antibody Directed against a Human Lymphoma-associated Antigen
Lee M. Nadler,Philip Stashenko,Russell Hardy,William D. Kaplan,Lawrence N. Button,Donald Kufe,Karen H. Antman,Stuart F. Schlossman +7 more
TL;DR: Preliminary evidence for the lack of clinical toxicity of a monoclonal antibody is provided and circulating blocking antigens as a significant obstacle to serotherapy are identified.